About Us

Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. Our lead program uses Heidelberg Pharma’s proprietary ATAC technology embracing innovative antibody design, linker technology and the payload amanitin to target Nectin-4 – an important and validated target for a broad range of cancers.

This approach brings the promise of superiority to enfortumab vedotin, a high-profile ADC for urothelial cancer which received US FDA accelerated approval in December 2019. We are also exploring opportunities to develop a broader pipeline of additional best- or first-in-class ADCs driven by therapeutic need.

Emergence is led by a strong management team supported by a network of world-leading experts in immuno-oncology and leading European investors.

Management
Team

Dr. Jack Elands
Chief Executive Officer
Carsten Dehning
Chief Financial Officer
Dr. Xavier Preville
Chief Scientific Officer
Dr. Florence Lhospice
Chief Development Officer

The
Board

Dr. Irina Staatz
Chairperson
Dr. Rakesh Dixit
Independent Director
Dr. Peter Neubeck
Director
Andreas Pahl
Director
Dr. Anke Cassing
Director
Dr. Olivier Martinez
Director
Dr. Telis Nastos
Director
Dr. Marek Kozlowski
Observer
Dr. Thierry Laugel
Observer

Scientific
Advisory Board

Dr. Xavier Preville
Chairman
Dr. Rakesh Dixit
Advisor & Collaborator
Robert Lutz
Advisor
John Lambert
Advisor
François Romagné
Advisor & Collaborator
Andreas Pahl
Advisor & Collaborator
Marc Lopez
Advisor & Collaborator
Daniel Olive
Advisor & Collaborator